Why the Immutep share price is halted today

Immutep shares are frozen as investors await a major trial update.

The Immutep Ltd (ASX: IMM) share price is currently halted on Monday. This comes after the biotech company requested a trading halt from the ASX late last week.

Before being placed on ice, shares in the cancer immunotherapy developer finished Friday's session up 3.95% to 39.5 cents.

Despite that gain, the stock has had a softer start to the year and remains around 5% lower in 2026.

Let's take a look at what is happening with this ASX healthcare share.

A man with a comical look on his face holds his hands in a 'time out' gesture.

Image source: Getty Images

Trading halt ahead of important clinical update

According to the release, Immutep requested that its shares be paused while it prepares to release a significant update to the market.

The pause relates to an upcoming update on the company's Phase III TACTI 004 clinical trial.

Management said the move is designed to ensure trading does not occur on an uninformed basis while the company prepares its announcement.

Immutep stated that the trading halt will remain in place until the earlier of an announcement being released or the commencement of trading on 11 March 2026.

Investors are now waiting for the company to disclose the results of the interim analysis.

What the clinical trial is testing

Immutep is an Australian biotechnology company developing new treatments that help the immune system fight cancer and other diseases.

Its lead drug candidate is called eftilagimod alpha. The treatment works by stimulating the body's immune system so it can better recognise and attack cancer cells.

The company is currently running a late-stage Phase III clinical trial known as TACTI 004, also called the KEYNOTE F91 study.

This trial is testing eftilagimod alpha alongside Keytruda, a widely used cancer treatment developed by pharmaceutical giant Merck.

The study focuses on patients with advanced head and neck cancer that has either returned or spread to other parts of the body.

As part of the trial, researchers are carrying out what is known as a futility analysis. This is an interim check to see whether the treatment appears likely to deliver positive results.

If the early data suggest the trial is on the right track, the study will continue. If not, researchers may decide it is unlikely to meet its goals.

Because this is a Phase III study, it is one of the final stages of clinical testing. The outcome of this analysis could have a major impact on Immutep's future.

What investors will be watching

Biotech shares often react strongly to clinical trial updates, particularly when they involve late-stage studies.

If the futility analysis indicates the trial should continue, it could strengthen investor confidence in Immutep's development pipeline.

However, if the results are disappointing, the market could react negatively.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »